Half-year report · HY
9627.TEDINET S100XAGJ
Period2025-05-01 → 2025-10-31
Filed2025-12-15
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥299.9bn | 2025-05-01 → 2025-10-31 | Cons. | Net sales |
| Revenue | ¥456.8bn | 2024-05-01 → 2025-04-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥214.9bn | 2024-05-01 → 2024-10-31 | Cons. | Net sales |
| Operating income | ¥10.5bn | 2025-05-01 → 2025-10-31 | Cons. | Operating income |
| Operating income | ¥5.9bn | 2024-05-01 → 2024-10-31 | Cons. | Operating income |
| Ordinary income | ¥9.9bn | 2025-05-01 → 2025-10-31 | Cons. | Ordinary income |
| Ordinary income | ¥18.1bn | 2024-05-01 → 2025-04-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥6.3bn | 2024-05-01 → 2024-10-31 | Cons. | Ordinary income |
| Profit before tax | ¥9.6bn | 2025-05-01 → 2025-10-31 | Cons. | Income before income taxes |
| Profit before tax | ¥6.7bn | 2024-05-01 → 2024-10-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥4.5bn | 2025-05-01 → 2025-10-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥9.3bn | 2024-05-01 → 2025-04-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥3.2bn | 2024-05-01 → 2024-10-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥4.5bn | 2025-05-01 → 2025-10-31 | Cons. | Profit loss |
| Net income | ¥3.2bn | 2024-05-01 → 2024-10-31 | Cons. | Profit loss |
| Total assets | ¥514.6bn | at 2025-10-31 | Cons. | Assets |
| Total assets | ¥311.9bn | at 2025-04-30 | Cons. | Assets |
| Total assets | ¥296.0bn | at 2024-10-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥369.1bn | at 2025-10-31 | Cons. | Liabilities |
| Total liabilities | ¥169.3bn | at 2025-04-30 | Cons. | Liabilities |
| Net assets / equity | ¥145.5bn | at 2025-10-31 | Cons. | Net assets |
| Net assets / equity | ¥142.6bn | at 2025-04-30 | Cons. | Net assets |
| Net assets / equity | ¥136.1bn | at 2024-10-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥53.1bn | at 2025-10-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥26.9bn | at 2025-04-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥52.8bn | at 2025-10-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥26.7bn | at 2025-04-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥27.2bn | at 2024-10-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥48.4bn | at 2024-04-30v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥1.2bn | 2025-05-01 → 2025-10-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥23.1bn | 2024-05-01 → 2025-04-30 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥12.7bn | 2024-05-01 → 2024-10-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥53.2bn | 2025-05-01 → 2025-10-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥65.9bn | 2024-05-01 → 2025-04-30 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥54.0bn | 2024-05-01 → 2024-10-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥78.2bn | 2025-05-01 → 2025-10-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥21.1bn | 2024-05-01 → 2025-04-30 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥20.1bn | 2024-05-01 → 2024-10-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥128.05 | 2025-05-01 → 2025-10-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥264.32 | 2024-05-01 → 2025-04-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥91.75 | 2024-05-01 → 2024-10-31 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 28.2% | at 2025-10-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 45.7% | at 2025-04-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 46.0% | at 2024-10-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 34
| Segment | Item | Period | Value |
|---|---|---|---|
| Otherother segments | revenue | 2025-05-01 → 2025-10-31 | ¥5.7bn |
| Otherother segments | revenue external | 2025-05-01 → 2025-10-31 | ¥5.5bn |
| Otherother segments | revenue intersegment | 2025-05-01 → 2025-10-31 | ¥134m |
| Otherother segments | segment ordinary income | 2025-05-01 → 2025-10-31 | ¥14m |
| Reconciling Itemsreconciling | revenue | 2025-05-01 → 2025-10-31 | −¥134m |
| Reconciling Itemsreconciling | revenue intersegment | 2025-05-01 → 2025-10-31 | −¥134m |
| Reconciling Itemsreconciling | segment ordinary income | 2025-05-01 → 2025-10-31 | −¥6.5bn |
| Dispensing Pharmacyreportable segment | revenue | 2025-05-01 → 2025-10-31 | ¥254.7bn |
| Dispensing Pharmacyreportable segment | revenue external | 2025-05-01 → 2025-10-31 | ¥254.7bn |
| Dispensing Pharmacyreportable segment | segment ordinary income | 2025-05-01 → 2025-10-31 | ¥12.8bn |
| Drug And Cosmetic Storereportable segment | revenue | 2025-05-01 → 2025-10-31 | ¥39.6bn |
| Drug And Cosmetic Storereportable segment | revenue external | 2025-05-01 → 2025-10-31 | ¥39.6bn |
| Drug And Cosmetic Storereportable segment | segment ordinary income | 2025-05-01 → 2025-10-31 | ¥3.5bn |
| —segment total | revenue | 2025-05-01 → 2025-10-31 | ¥300.0bn |
| —segment total | revenue external | 2025-05-01 → 2025-10-31 | ¥299.9bn |
| —segment total | revenue intersegment | 2025-05-01 → 2025-10-31 | ¥134m |
| —segment total | segment ordinary income | 2025-05-01 → 2025-10-31 | ¥16.4bn |
| Otherother segments | revenue | 2024-05-01 → 2024-10-31 | ¥5.6bn |
| Otherother segments | revenue external | 2024-05-01 → 2024-10-31 | ¥5.5bn |
| Otherother segments | revenue intersegment | 2024-05-01 → 2024-10-31 | ¥24m |
| Otherother segments | segment ordinary income | 2024-05-01 → 2024-10-31 | −¥15m |
| Reconciling Itemsreconciling | revenue | 2024-05-01 → 2024-10-31 | −¥24m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-05-01 → 2024-10-31 | −¥24m |
| Reconciling Itemsreconciling | segment ordinary income | 2024-05-01 → 2024-10-31 | −¥5.0bn |
| Dispensing Pharmacyreportable segment | revenue | 2024-05-01 → 2024-10-31 | ¥186.4bn |
| Dispensing Pharmacyreportable segment | revenue external | 2024-05-01 → 2024-10-31 | ¥186.4bn |
| Dispensing Pharmacyreportable segment | segment ordinary income | 2024-05-01 → 2024-10-31 | ¥9.6bn |
| Drug And Cosmetic Storereportable segment | revenue | 2024-05-01 → 2024-10-31 | ¥22.9bn |
| Drug And Cosmetic Storereportable segment | revenue external | 2024-05-01 → 2024-10-31 | ¥22.9bn |
| Drug And Cosmetic Storereportable segment | segment ordinary income | 2024-05-01 → 2024-10-31 | ¥1.7bn |
| —segment total | revenue | 2024-05-01 → 2024-10-31 | ¥214.9bn |
| —segment total | revenue external | 2024-05-01 → 2024-10-31 | ¥214.9bn |
| —segment total | revenue intersegment | 2024-05-01 → 2024-10-31 | ¥24m |
| —segment total | segment ordinary income | 2024-05-01 → 2024-10-31 | ¥11.3bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 581
| Item | Context | Value | Unit |
|---|---|---|---|
| Increase decrease in provision for directors bonuses ope cf | Prior1InterimDuration | -2000000 | JPY |
| Increase decrease in provision for directors bonuses ope cf | InterimDuration | 4000000 | JPY |
| Interest and dividends income ope cf | Prior1InterimDuration | -34000000 | JPY |
| Interest and dividends income ope cf | InterimDuration | -96000000 | JPY |
| Interest expenses ope cf | Prior1InterimDuration | 84000000 | JPY |
| Interest expenses ope cf | InterimDuration | 882000000 | JPY |
| Loss gain on investments in partnership ope cf | Prior1InterimDuration | -6000000 | JPY |
| Loss gain on investments in partnership ope cf | InterimDuration | -3000000 | JPY |
| Gain on donation of noncurrent assets ope cf | Prior1InterimDuration | -8000000 | JPY |
| Gain on donation of noncurrent assets ope cf | InterimDuration | -16000000 | JPY |
| Loss gain on sales of investment securities ope cf | Prior1InterimDuration | -18000000 | JPY |
| Loss gain on sales of investment securities ope cf | InterimDuration | -27000000 | JPY |
| Loss gain on valuation of investment securities ope cf | Prior1InterimDuration | 43000000 | JPY |
| Loss gain on valuation of investment securities ope cf | InterimDuration | 16000000 | JPY |
| Loss gain on sales and retirement of noncurrent assets ope cf | Prior1InterimDuration | 34000000 | JPY |
| Loss gain on sales and retirement of noncurrent assets ope cf | InterimDuration | 243000000 | JPY |
| Decrease increase in notes and accounts receivable trade ope cf | Prior1InterimDuration | 2094000000 | JPY |
| Decrease increase in notes and accounts receivable trade ope cf | InterimDuration | -12871000000 | JPY |
| Decrease increase in inventories ope cf | Prior1InterimDuration | -3085000000 | JPY |
| Decrease increase in inventories ope cf | InterimDuration | -2224000000 | JPY |
| Decrease increase in other assets ope cf | Prior1InterimDuration | 529000000 | JPY |
| Decrease increase in other assets ope cf | InterimDuration | 396000000 | JPY |
| Decrease increase in accounts receivable other ope cf | Prior1InterimDuration | -1979000000 | JPY |
| Decrease increase in accounts receivable other ope cf | InterimDuration | 3257000000 | JPY |
| Increase decrease in notes and accounts payable trade ope cf | Prior1InterimDuration | 5920000000 | JPY |
| Increase decrease in notes and accounts payable trade ope cf | InterimDuration | 1421000000 | JPY |
| Increase decrease in other liabilities ope cf | Prior1InterimDuration | 140000000 | JPY |
| Increase decrease in other liabilities ope cf | InterimDuration | -4903000000 | JPY |
| Subtotal ope cf | Prior1InterimDuration | 17384000000 | JPY |
| Subtotal ope cf | InterimDuration | 5931000000 | JPY |
| Interest and dividends income received ope cf inv cf | Prior1InterimDuration | 34000000 | JPY |
| Interest and dividends income received ope cf inv cf | InterimDuration | 90000000 | JPY |
| Interest expenses paid ope cf fin cf | Prior1InterimDuration | -65000000 | JPY |
| Interest expenses paid ope cf fin cf | InterimDuration | -902000000 | JPY |
| Income taxes paid ope cf | Prior1InterimDuration | -4624000000 | JPY |
| Income taxes paid ope cf | InterimDuration | -3893000000 | JPY |
| Net cash provided by used in operating activities | Prior1InterimDuration | 12729000000 | JPY |
| Net cash provided by used in operating activities | InterimDuration | 1225000000 | JPY |
| Purchase of property plant and equipment inv cf | Prior1InterimDuration | -4266000000 | JPY |
| Purchase of property plant and equipment inv cf | InterimDuration | -5579000000 | JPY |
| Proceeds from sales of property plant and equipment inv cf | Prior1InterimDuration | 621000000 | JPY |
| Proceeds from sales of property plant and equipment inv cf | InterimDuration | 489000000 | JPY |
| Purchase of investment securities inv cf | Prior1InterimDuration | -0 | JPY |
| Purchase of investment securities inv cf | InterimDuration | -313000000 | JPY |
| Proceeds from sales of investment securities inv cf | Prior1InterimDuration | 301000000 | JPY |
| Proceeds from sales of investment securities inv cf | InterimDuration | 178000000 | JPY |
| Purchase of investments in subsidiaries resulting in change in scope of consolidation inv cf | Prior1InterimDuration | -46471000000 | JPY |
| Purchase of investments in subsidiaries resulting in change in scope of consolidation inv cf | InterimDuration | -45175000000 | JPY |
| Payments of loans receivable inv cf | Prior1InterimDuration | -103000000 | JPY |
| Payments of loans receivable inv cf | InterimDuration | -31000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |